When Should You Buy Sinopharm Group Co. Ltd. (HKG:1099)?
When Should You Buy Sinopharm Group Co. Ltd. (HKG:1099)?
Sinopharm Group Co. Ltd. (HKG:1099), is not the largest company out there, but it received a lot of attention from a substantial price movement on the SEHK over the last few months, increasing to HK$22.55 at one point, and dropping to the lows of HK$17.84. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Sinopharm Group's current trading price of HK$17.84 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Sinopharm Group's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
国药控股有限公司(HKG:1099)不是最大的公司,但在过去几个月的时间里,在SEHk上出现了大幅的价格波动,最高曾上涨至HK$22.55,最低跌至HK$17.84。有些股价的波动可以为投资者提供更好的机会进入股票市场,以及在更低的价格购入股票。需要回答的问题是,国药控股的当前交易价格HK$17.84是否反映了中型公司的实际价值?还是它现在被低估,为我们提供了购买股票的机会?让我们根据最近的财务数据来看一下国药控股的前景和价值,以确定是否存在价格变动的催化剂。
What Is Sinopharm Group Worth?
国药控股的价值是多少?
Great news for investors – Sinopharm Group is still trading at a fairly cheap price according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. we find that Sinopharm Group's ratio of 5.82x is below its peer average of 10.97x, which indicates the stock is trading at a lower price compared to the Healthcare industry. What's more interesting is that, Sinopharm Group's share price is quite stable, which could mean two things: firstly, it may take the share price a while to move closer to its industry peers, and secondly, there may be less chances to buy low in the future once it reaches that value. This is because the stock is less volatile than the wider market given its low beta.
对于投资者来说,有一个好消息——国药控股仍然按照我们的价格多项模型,按照其市盈率与行业平均值进行比较,价格相对较低。在这种情况下,我们使用市盈率(PE)比率,因为没有足够的信息来可靠地预测股票的现金流。我们发现,国药控股的比率为5.82倍,低于其同行业平均水平的10.97倍,这表明该股在医疗保健行业中的交易价格较低。更有趣的是,国药控股的股价相当稳定,这可能意味着两件事情,首先,股价可能需要一段时间才能接近其同行业标准,其次,一旦达到该价值,未来买入的机会可能会减少。这是因为该股的波动性要比整个市场低,因为它的贝塔较低。
Can we expect growth from Sinopharm Group?
我们能否期望国药控股有增长?
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240731/0-ff14399abc5eb28e53d3e8a6252052de-0-3a3ed8bc069aaf10a4c281023fcc2e62.png/big)
Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by 21% over the next couple of years, the future seems bright for Sinopharm Group. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.
如果投资者想在其组合中寻找增长,可能需要在购买其股票之前考虑该公司的前景。以低廉的价格购买一家具有强劲前景的优秀公司是一项好的投资。让我们再来看一下公司的未来展望。预计未来几年的利润将增长21%,国药控股的未来看上去光明。看起来股票的现金流是即将到来的,这应该会推高股票的估价。
What This Means For You
这对您意味着什么?
Are you a shareholder? Since 1099 is currently below the industry PE ratio, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current price multiple.
您是一位股东吗?由于1099目前低于同行业市盈率,购买更多的股票可能是一个不错的时机。随着乐观的前景,似乎这种增长还没有完全反映在股价上。然而,还有其他因素需要考虑,例如资本结构,这可能解释了当前的价格倍数。
Are you a potential investor? If you've been keeping an eye on 1099 for a while, now might be the time to enter the stock. Its buoyant future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy 1099. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.
您是潜在投资者吗?如果您一直在关注1099,现在可能是进入该股票的时候了。它仍未完全反映其未来利润前景的乐观和光明,这意味着购买1099还不算晚。但在作出任何投资决策之前,请考虑其他因素,例如管理团队的业绩记录,以便做出明智的投资决策。
Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. So feel free to check out our free graph representing analyst forecasts.
由于个别股票选择的时间非常重要,因此有必要查看最新的分析师预测。因此,可以免费查看表示分析师预测的免费图表。
If you are no longer interested in Sinopharm Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
如果您已不再对国药控股感兴趣,您可以使用我们的免费平台查看我们列出的其他50多个具有高增长潜力的股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。